Serabiotics

Executive Summary

Serabiotics is a Spanish biotechnology company that specializes in developing advanced technologies from human plasma for non-therapeutic applications. Founded in 2015 and based in Madrid, the company leverages its expertise in isolating and purifying plasma components such as growth factors, cytokines, and extracellular matrix proteins. Its primary focus areas include assisted reproduction, cell therapy, and regenerative medicine, where it aims to revolutionize current practices by providing high-quality, biologically derived products that enhance cell culture, tissue regeneration, and reproductive outcomes. Given its position as a private, early-stage company with no disclosed funding or stage, Serabiotics represents a niche player in the biologics space. Its plasma-derived technologies offer potential advantages over recombinant alternatives in terms of bioactivity and cost. However, the lack of publicly available data on revenue, clinical progress, or partnerships limits visibility. The company's success hinges on establishing collaborations with fertility clinics and cell therapy developers, as well as navigating regulatory pathways for its products. With a focused approach on non-therapeutic uses, Serabiotics may avoid some of the lengthy clinical trial timelines seen in traditional therapeutics, potentially accelerating time to market.

Upcoming Catalysts (preview)

• Q4 2026Partnership with a major fertility clinic network for plasma-derived media products40% success
• Q1 2027Launch of a commercially available cell therapy supplement (e.g., platelet lysate)35% success
• Q2 2027Series A funding round announcement50% success